Semaglutide purity.

Semaglutide is a 31-residue synthetic peptide originated by Novo Nordisk under the development code NN9535. Its release-time purity is a strictly compositional statement: the fraction of UV-detectable material in the HPLC chromatogram that corresponds to the Semaglutide peak, integrated at a defined wavelength on a defined chromatographic system and reported as area-percent.

Purity is not the same as identity. Purity asks how much of the target is present; identity asks whether the target is the correct chemical entity. Semaglutide is a lipidated GLP-1 analogue whose C18 fatty-diacid Lys26 modification and Aib8 substitution must be present intact — a mass-spectrometric identity result is what confirms them. A meaningful release specification always reports both numbers side by side.

Semaglutide is the reference selective GLP-1 receptor agonist in modern incretin pharmacology. Comparative cAMP dose–response, receptor-binding and signalling-bias studies against tirzepatide (dual) and retatrutide (triple) rely on the assumption that the Semaglutide input is compositionally clean. Related-substance impurities — desamido, oxidised methionine, or free-acid lipidation variants — can shift potency, distort the reference curve and propagate error across every derived comparison.

Reproducibility is the second reason. Batch-to-batch impurity drift is one of the most common sources of unexplained variance in receptor pharmacology. A transparent ≥99% HPLC-UV release specification, retained samples and a public verification library let any laboratory tie an anomalous result back to the exact analytical record for the Semaglutide batch in use. The broader published-evidence base for the peptide lives on the Semaglutide research page.

Reversed-phase HPLC is the reference technique. Semaglutide is resolved on a C18 stationary phase (typically 3–5 µm particles, 100–300 Å pores) under an aqueous / acetonitrile gradient modified with 0.1% trifluoroacetic acid as an ion-pairing agent. The lipidated Lys26 side-chain makes the peptide more hydrophobic than the unmodified GLP-1 backbone, so it elutes later than closely related deletion or free-acid variants — the resolution that lets those species be quantified individually.

UV detection is set at 214 nm, capturing amide-bond absorbance directly. Purity is computed by integrating every resolved peak, dividing the Semaglutide peak area by the total integrated area, and expressing the result as area-percent. Consistent integration parameters and method-suitability checks between injection sequences are what make the reported ≥99% figure comparable across batches.

Identity is confirmed by electrospray-ionisation mass spectrometry. The Semaglutide sample is ionised, and the resulting multi-charge envelope is deconvoluted to yield the intact mass. That value is compared against the theoretical monoisotopic mass calculated from the NN9535 sequence — approximately 4113.6 Da for the C₁₈₇H₂₉₁N₄₅O₅₉ composition — within the mass-accuracy tolerance of the instrument.

Where higher structural confidence is needed, tandem MS/MS fragmentation can localise modifications such as the C18 fatty-diacid on Lys26 or the α-aminoisobutyric acid substitution at position 8. Both the HPLC-UV purity value and the ESI-MS identity result are recorded on the batch Certificate of Analysis.

Every BuyRetaUK Semaglutide vial carries a batch number printed on the label. That batch number resolves to a single analytical record — HPLC-UV chromatogram, mass spectrum, appearance and, where determined, moisture and endotoxin — held on file and mirrored in the public verification library.

Bench verification is a two-step check: read the batch number from the vial, then confirm the matching COA in the library reports the release specification you expected. A missing batch number, a purity value below release specification, or an inconclusive identity result should stop use of that vial until the anomaly is resolved with the supplier.

A Semaglutide COA is the batch's formal release document. Expect to see: compound name (Semaglutide / NN9535), batch identifier, appearance, HPLC-UV area-percent purity, ESI-MS identity result, largest single impurity, total impurities, water content where determined and endotoxin where applicable. Any field marked "not determined" should be interpreted deliberately — a COA is only informative for what it explicitly reports.

The section-by-section anatomy of a peptide COA, with worked examples, is covered in the Certificate of Analysis guide.

Semaglutide is released against the peptide-specific quality attributes described in USP General Chapter <1503>, the specification framework of ICH Q6A, the impurity thresholds informed by ICH Q3A(R2), and analytical procedures qualified under ICH Q2(R2). Method suitability, retained samples and supplier qualification are documented once on the laboratory quality page and kept concise here to avoid duplication.